Vernalis receives milestone payment in Hsp90 inhibitor collaboration
20-Jul-2009
- USA
Ian Garland, CEO of Vernalis said “We are delighted that Novartis is now progressing two Hsp90 inhibitors in human clinical studies. Milestones and royalties are receivable on both programmes as they progress through development and into commercialisation."
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.